FindTrial
Sign In

A phase I study of irinotecan for previously treated lung cancer patients with UGT1A1*28 or *6 polymorphism

A phase I study of irinotecan for previously treated lung cancer patients with UGT1A1*28 or *6 polymorphism - Irinotecan PI for UGT1A1*28*6 lung cancer

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006095
Enrollment
15
Registered
2011-08-01
Start date
2011-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Irinotecan

Sponsors

Lung Oncology Group in Kyusyu, Japan (LOGiK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: histologically confirmed lung cancer previously treated by agents except irinotecan UGT1A1*28 or UGT1A1*6 polymorphism PS 0-1 adequate organ function written informed consent

Exclusion criteria

Exclusion criteria: Interstitial pneumonia detected by Chest X-ray cardiac and pleural effusion, SVC syndrome, and brain metastasis for necessary treatment active duplicative cancer for necessary chemotherapy pregnant or possible pregnant women difficult to attend study by psychiatric illness high fever more than 38 degrees severe complication (myocardial infarction within 3 months, difficult to control angina, heart failure, diabetes, and hypertension ) diarrhea bowel paralysis or ileus

Design outcomes

Primary

MeasureTime frame
recommended dose—

Secondary

MeasureTime frame
dose limiting toxicity, maximum tolerated dose—

Countries

Japan

Contacts

Public ContactMinoru Fukuda

Japanese red cross nagasaki genbaku hospital Division of chemotherapy

mifukuda258@nifty.com095-819-7779

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026